Table 1.
Demographic data of patients under the study
| Characteristics | Case group (n = 76) | Control group (n = 60) | P value | ||
|---|---|---|---|---|---|
| Patients with clinically localized PCA (n = 50) | Patients with metastatic PCA (n = 26) | BPH (n = 50) | Normal (n = 10) | ||
| Age (years) Mean ± SD | 63.16 ± 4.50 | 66.26 ± 4.37 | 61.42 ± 5.62 | 61.00 ± 3.91 | 0.097 |
| Range | 55-70 | 55-72 | 54-76 | 55-68 | |
| ≤65 n (%) | 34 (68.00) | 9 (34.61) | 37 (74.00) | 8 (80.00) | |
| >65 n (%) | 16 (32.00) | 17 (65.39) | 13 (26.00) | 2 (20.00) | |
| Gleason scores | 0.000 | ||||
| ≤7 n (%) | 49 (98.00) | 17 (65.38) | - | - | |
| >7 n (%) | 1 (2.00) | 9 (34.62) | - | - | |
| Serum PSA (ng/mL) | 0.001 | ||||
| Mean level ± SD | 18.48 ± 2.28 | 28.20 ± 3.46 | 7.93 ± 3.71 | 1.42 ± 0.72 | |
| Range | 4.50-112.0 | 5.90-121.0 | 1.27-20.5 | 0.50-2.50 | |
| cfDNA level (ng/µl) | 0.000 | ||||
| Mean level ± SD | 15.04 ± 3.21 | 19.62 ± 4.82 | 9.51 ± 2.13 | 7.8 ± 1.29 | |
| Range | 10.5-25.10 | 12.5-31.30 | 6.30-14.5 | 6-10 | |